30
Registered trials
15
Recruiting
12
Completed trials
21
Sponsors
17
Countries
Phase III:
7
Phase II:
17
Phase I/II:
3
Phase I:
1
Phase I (FiH):
2
Oversight events:
4 serious breaches
7 temporary halts
1 unexpected event
across 4 trials
View oversight register →
Indications tested
Non-small cell lung cancer
3
Squamous cell carcinoma of head and neck
2
Colorectal cancer
2
Small cell lung cancer extensive stage
1
Adenocarcinoma gastric
1
Renal cell carcinoma
1
Squamous cell carcinoma of the oral cavity
1
Gastrooesophageal cancer
1
Gastric cancer
1
Rectal cancer stage III
1
Soft tissue sarcoma
1
Rectal cancer stage II
1
Sponsors using this IMP
BeOne Medicines AG
4
Beigene Ltd.
2
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
2
Novartis Pharma AG
2
Oncomatryx Biopharma S.A.
2
Oslo University Hospital HF
2
Solti Group
2
University Of Cologne
2
Fondazione GONO Plus
1
Fondazione Italiana Linfomi Onlus
1
Fondazione Ricerca Traslazionale
1
Grupo Espanol Multidisciplinar De Melanoma
1
All trials — page 2
30 totalShowing 25–30 of 30 trials